Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

[1]  K. Rahimi,et al.  Multi-morbidity and blood pressure trajectories in hypertensive patients: A multiple landmark cohort study , 2021, PLoS medicine.

[2]  R. Collins,et al.  Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis , 2021, The Lancet.

[3]  B. Davis,et al.  Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis , 2021, The Lancet. Oncology.

[4]  B. Davis,et al.  Effect of antihypertensive drug treatment on long-term blood pressure reduction: An individual patient-level data meta-analysis of 352,744 Participants from 51 large-scale randomised clinical trials , 2021, medRxiv.

[5]  K. Rahimi,et al.  Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK , 2021, Open Heart.

[6]  B. Davis,et al.  Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis , 2020, PLoS medicine.

[7]  M. Budoff,et al.  Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors. , 2020, JAMA cardiology.

[8]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.

[9]  R. Payne,et al.  Generalizability of Blood Pressure Lowering Trials to Older Patients: Cross‐Sectional Analysis , 2020, Journal of the American Geriatrics Society.

[10]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.

[11]  A. Wierzbicki,et al.  Hypertension in adults: summary of updated NICE guidance , 2019, BMJ.

[12]  K. Rahimi,et al.  Blood pressure management in the elderly: the need for more randomised evidence , 2019, Heart.

[13]  M. Jung,et al.  Age-specific associations between systolic blood pressure and cardiovascular mortality , 2019, Heart.

[14]  B. Davis,et al.  Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) , 2019, BMJ Open.

[15]  T. Strandberg,et al.  Hypertension Management in Older and Frail Older Patients , 2019, Circulation research.

[16]  J. Williamson,et al.  Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.

[17]  L. Appel,et al.  Association of Age With Blood Pressure Across the Lifespan in Isolated Yanomami and Yekwana Villages , 2018, JAMA cardiology.

[18]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[19]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[20]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[21]  K. Rahimi,et al.  Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study , 2018, PLoS medicine.

[22]  P. Muntner,et al.  Response to Letter to editor "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". , 2018, Journal of the American Society of Hypertension : JASH.

[23]  T. Wilt,et al.  Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians , 2017, Annals of Internal Medicine.

[24]  D. Kansagara,et al.  Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older , 2017, Annals of Internal Medicine.

[25]  Sungha Park,et al.  Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure. , 2016, Journal of the American Society of Hypertension : JASH.

[26]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[27]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[28]  Mark Woodward,et al.  Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke , 2016, Stroke.

[29]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[30]  Mark Woodward,et al.  Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults , 2015, BMJ : British Medical Journal.

[31]  K. Rahimi,et al.  The epidemiology of blood pressure and its worldwide management. , 2015, Circulation research.

[32]  T. Ogihara,et al.  Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1 , 2014, Journal of hypertension.

[33]  Emanuela Falaschetti,et al.  Hypertension management in England: a serial cross-sectional study from 1994 to 2011 , 2014, The Lancet.

[34]  Harry Hemingway,et al.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.

[35]  J. Staessen,et al.  Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure , 2012, Hypertension Research.

[36]  T. Ogihara,et al.  Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial , 2011, Journal of hypertension.

[37]  M. Pfeffer,et al.  Irbesartan in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[38]  Keith C. Norris,et al.  Intensive blood-pressure control in hypertensive chronic kidney disease. , 2010, The New England journal of medicine.

[39]  T. Ogihara,et al.  Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study , 2010, Hypertension.

[40]  T. Ogihara,et al.  Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial , 2010, Hypertension Research.

[41]  J. Staessen,et al.  Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial , 2009, The Lancet.

[42]  Y. Gustafson,et al.  Lower Systolic Blood Pressure Is Associated with Greater Mortality in People Aged 85 and Older , 2008, Journal of the American Geriatrics Society.

[43]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[44]  Vivian Gu,et al.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.

[45]  B Neal,et al.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials , 2008, BMJ : British Medical Journal.

[46]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[47]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[48]  T. Ogihara,et al.  Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.

[49]  P. Williamson,et al.  A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes , 2007, Clinical trials.

[50]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[51]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[52]  R. Westendorp,et al.  In a population-based prospective study, no association between high blood pressure and mortality after age 85 years , 2006, Journal of hypertension.

[53]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[54]  Y. Kanno,et al.  Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients , 2005, Hypertension Research.

[55]  M. Mauer,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[56]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[57]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[58]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[59]  S. Hosoda,et al.  Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[60]  J. Ménard,et al.  Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) , 2004, BMJ : British Medical Journal.

[61]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[62]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[63]  Peter Sleight,et al.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. , 2003, JAMA.

[64]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[65]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[66]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[67]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[68]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[69]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[70]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[71]  J. Goodwin,et al.  The Relationship Between Blood Pressure and Mortality in the Oldest Old , 2001, Journal of the American Geriatrics Society.

[72]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[73]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[74]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[75]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[76]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[77]  A. Zanchetti,et al.  The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.

[78]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[79]  R. Schrier,et al.  Appropriate Blood Pressure Control in NIDDM (ABCD) Trial , 1996, Diabetologia.

[80]  Les M Irwig,et al.  An evidence based approach to individualising treatment , 1995, BMJ.

[81]  A. Algra,et al.  Risk of cardiac events in atypical transient ischaemic attack or minor stroke , 1992, The Lancet.

[82]  P. Elliott,et al.  Blood Pressure in Four Remote Populations in the INTERSALT Study , 1989, Hypertension.

[83]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[84]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.

[85]  A. Doyle.  The Australian National Blood Pressure Study. , 1981, Australian family physician.

[86]  D. Melzer,et al.  Blood Pressure Trajectories in the 20 Years Before Death , 2018, JAMA internal medicine.

[87]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[88]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[89]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[90]  H. Gavras.  Effect of ramipril on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[91]  Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. , 1999, Hypertension.

[92]  Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. 1979. , 1997, JAMA.